Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vivek Bhaktaram

Interventional Cardiology Oklahoma City, OK Medical Doctor

NPI 1760588545 CMS profile 216508

5224 E I 240 Service Rd Ste 100, Oklahoma City, OK 73135

Open in the dashboard

General payments

$8,451

354 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Vivek Bhaktaram of Oklahoma City, OK is reported in the CMS Open Payments database as having received $8,451 across 354 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $774 30
2024 General $1,331 54
2023 General $1,318 64
2022 General $1,226 48
2021 General $1,706 57
2020 General $679 22
2019 General $1,417 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vivek Bhaktaram
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Vivek Bhaktaram were reported at $774. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Vivek Bhaktaram Interventional Cardiology median Middle half National median
2019 $1,417 $1,097 $329–$3,048 $163
2020 $679 $473 $161–$1,480 $114
2021 $1,706 $677 $233–$1,827 $132
2022 $1,226 $978 $333–$2,724 $149
2023 $1,318 $1,136 $382–$2,986 $160
2024 $1,331 $1,181 $395–$3,326 $164
2025 $774 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $1,082 61 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $830 32 payments
  3. Novo Nordisk Inc $735 20 payments
  4. Amgen Inc. $714 40 payments
  5. Novartis Pharmaceuticals Corporation $669 36 payments
  6. Merck Sharp & Dohme Corporation $607 30 payments
  7. AstraZeneca Pharmaceuticals LP $605 13 payments
  8. E.R. Squibb & Sons, L.L.C. $532 27 payments
  9. Esperion Therapeutics, Inc. $497 10 payments
  10. Abiomed $345 3 payments
  11. Other $1,835 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,451 354 payments
Products named General payments · program years 2019–2025
  1. XARELTO $1,082 61 payments
  2. VERQUVO $919 41 payments
  3. Repatha $694 39 payments
  4. FARXIGA $509 5 payments
  5. NEXLETOL $497 10 payments
  6. Ozempic $497 13 payments
  7. JARDIANCE $494 26 payments
  8. Corlanor $449 25 payments
  9. ELIQUIS $416 19 payments
  10. NEXLIZET $373 3 payments
  11. Other $4,070 183 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 45 drugs

Part D claims

4,325

Median for Interventional Cardiology: 2,236

Drug cost

$442,470

Median for Interventional Cardiology: $380,412

Branded share of claims

16%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 150 $149,953
Entresto Sacubitril/Valsartan Brand 53 $65,538
Repatha Sureclick Evolocumab Brand 53 $54,411
Jardiance Empagliflozin Brand 44 $50,151
Xarelto Rivaroxaban Brand 25 $34,685
Januvia Sitagliptin Phosphate Brand 17 $16,365
Brilinta Ticagrelor Brand 11 $12,096
Atorvastatin Calcium Generic 647 $7,956
Metoprolol Succinate Generic 516 $6,864
Ezetimibe Generic 229 $6,579

The 10 drugs with the highest cost, of 45 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$66,522

Medicare's payments for the services billed

Medicare patients

949

Average age 76

Services billed

2,108

482 women, 467 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 72%
Arthritis 56%
Diabetes 46%
Atrial fibrillation 37%
Heart failure 36%
Chronic kidney disease 35%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $324
$324 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $151
$151 44 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $147
$147 — —
Repatha
  • Amgen Inc. $94
$94 53 —
XARELTO
  • Janssen Pharmaceuticals, Inc $71
$71 25 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

354 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record